NCT05829551View on ClinicalTrials.gov

The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
DRUG

RAY1216 dose 1

RAY1216 dose 1 or Placebo

DRUG

RAY1216 dose 2

RAY1216 dose 2 or Placebo

DRUG

RAY1216 dose 3

RAY1216 dose 3 or Placebo

DRUG

RAY1216 dose 4 &ritonavir

RAY1216 dose 4 \&ritonavir or Placebo

DRUG

RAY1216 dose 5

RAY1216 dose 5 or Placebo

DRUG

RAY1216 dose 6

RAY1216 dose 6 or Placebo

DRUG

RAY1216 dose 7

RAY1216 dose 7 or Placebo

DRUG

RAY1216 dose 8

RAY1216 dose 8 or Placebo

DRUG

RAY1216 dose 9

RAY1216 dose 9 or Placebo with high fat meal

DRUG

RAY1216 dose 10

RAY1216 dose 10 or Placebo with high fat meal

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Jilin

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY